SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing massive volatility fueled by an extreme short squeeze where concentrated institutional ownership has effectively locked up the available float. The community is actively debating the sustainability of this parabolic move, with many traders drawing parallels to historic short squeezes while others warn of a potential crash triggered by looming debt concerns and the possibility of equity dilution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to management's bullish commentary regarding upcoming purchase orders and confirmed customer engagements. Community sentiment is highly optimistic, with many traders discussing the stock's potential for a sustained breakout as the company shifts from product development to commercial scaling.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh strong Q1 revenue and a massive $695 billion backlog against ongoing delivery constraints and cash flow pressures. The community is actively discussing the company's turnaround potential, focusing on the upcoming 737 MAX certification timeline and whether current price action represents a value opportunity or further downside risk before margins stabilize.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the FCC's grant of full commercial approval for its 248-satellite constellation, a major regulatory catalyst the community believes effectively de-risks the company's business model. Investors are actively debating the potential for a short squeeze as the stock rebounds from recent launch volatility, with many highlighting the significance of nationwide spectrum integration alongside key telecom partnerships.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending as investors weigh its inclusion in the S&P 500 against concerns that the stock has become overvalued following an aggressive rally driven by AI data center infrastructure demand. The community remains deeply divided, with some betting on long-term growth supported by a record backlog and liquid cooling leadership, while others point to institutional profit-taking and technical indicators suggesting a potential pullback.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant market interest driven by its role as a power semiconductor partner for next-generation AI data center architectures, specifically regarding its gallium nitride (GaN) technology. While the community is actively debating the sustainability of its current valuation and potential volatility ahead of upcoming earnings, bulls are highlighting long-term design wins and institutional interest as catalysts for continued growth.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as the market reacts to the Trump administration's initiative to force technology companies to fund $15 billion in new power plant construction to support surging AI data center energy demands. Investors are closely monitoring the stock as a key equipment provider in this infrastructure cycle, while community discussions remain focused on potential margin expansion, order backlog growth, and the broader shift in the power sector landscape.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing heightened activity as investors pivot between speculative anticipation ahead of upcoming earnings and frustration over long-term timelines for commercialization. The community remains deeply divided, with some betting on a short squeeze fueled by elevated short interest and recent high-profile board appointments, while others warn of potential downside due to the lack of significant revenue catalysts.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is experiencing intense bullish momentum and short-squeeze chatter, driven by a combination of retail FOMO, institutional upgrades, and significant optimism surrounding its expanding role in AI infrastructure and CPU demand. While bulls remain confident in the stock's path toward new highs, the community is actively debating whether the current rapid ascent is a sustainable growth trajectory or an overextended move vulnerable to a sharp pullback.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is surging as investors react to positive long-term Phase 2 trial results for its lead CAR-T therapy, miv-cel, in treating both stiff person syndrome and generalized myasthenia gravis. The community is heavily focused on the drug's potential as a 'first-in-class' autoimmune treatment, with active discussions centering on upcoming BLA filings, analyst upgrades, and the high probability of a future buyout by a major pharmaceutical partner.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.&nbsp;</li><li>The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91.</li><li>Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer.</li></ul>Shares of Atossa Therapeutics (ATOS) slipped 4% after hours on Wednesday after the company said that it continues to align its resources towards potential commercialization of (Z)-endoxifen after it reported a wider full year loss.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atossatherapeutics.com/2026-03-25-Atossa-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-a-Corporate-Update">said</a> that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer. The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.“We believe these FDA designations are important for future development as they both help to speed the FDA review process as well as provide potential financial benefits in the future," CEO Steven Quay said on Wednesday.Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer due to the overall cost and timeline required to conduct later-stage studies in the indication. The company then said it will prioritize its resources on other oncology and rare disease areas with “higher potential returns on investments.”<h2 class="st-heading-2">Q4 Earnings</h2>The company said on Wednesday that its operating expenses rose in 2025 to $37.1 million, compared to $9.5 million in 2024, owing to a significant rise in research and development expenses for (Z)-endoxifen.The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91. The company ended the year with cash and cash equivalents of $41.29 million, compared to $71.08 million as of 2024-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has dropped 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/wkhs-stock-rallies-after-hours-on-unveiling-cheaper-electric-delivery-van/cZ3pPW4RIjI">WKHS Stock Rallies After Hours On Unveiling Cheaper Electric Delivery Van</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.

Equity

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.


Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two...

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference Atossa Therapeutics Presents Clinical Trial Update Highlighting...

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - What's Next?

Atossa Genetics (NASDAQ:ATOS) Sees Large Volume Increase - Still a Buy...

<ul class="summary-bullets"><li>Each of 15 shares of the company’s common stock outstanding was combined into one new share of common stock.</li><li>No fractional shares were issued as a result of the split.&nbsp;</li><li>In January, the FDA granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy.</li></ul>Shares of Atossa Therapeutics Inc. (ATOS) fell a steep 32% on Monday after the stock began trading on a split adjusted basis at trade open.Atossa <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526021727/atos-20260120.htm">said</a> last week that its Board of Directors has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026.Each of 15 shares of the company’s common stock outstanding was combined into one new share that started trading on a split-adjusted basis on Monday. No fractional shares were issued as a result of the split.<h2 class="st-heading-2">New Designations</h2>In January, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Atossa’s (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The drug was previously granted Rare Pediatric Disease designation for the treatment of DMD as well.Duchenne muscular dystrophy is a severe, progressive, X-linked genetic disorder, primarily affecting boys, characterized by the lack of the protein dystrophin, leading to muscle degeneration.The orphan drug designation is granted to therapies intended to treat rare diseases and offers incentives such as regulatory support. The drug is yet to be approved for any indication. However, the FDA gave clearances for studying the drug in metastatic breast cancer earlier in January.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory, while message volume remained at ‘high’ levels.A Stocktwits user highlighted concerns about a potential dilution. The company has cash and cash equivalents of $51.8 million as of September end. &nbsp;<stembedurl>https://www.stocktwits.com/St0ckt0k101/message/643702353</stembedurl>Another said that they are “relieved” the company didn’t get delisted.<stembedurl>https://www.stocktwits.com/RealTurd/message/643701100</stembedurl><a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has lost 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2, 2026. 

Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,621,023...

Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd

Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) shares are going to reverse split on the morning of Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of...

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Current Price	$5.77
Prev Close	$6.17
Open	$6.20
Dividend Yield	0.00%
50-Day Moving Average	$4.90
Beta	1.32
Avg. Volume	85,508.98
PE Ratio	-1.43

52-Week High	$19.35
52-Week Low	$3.76
Market Capitalization	$49.69M
EPS (Annual)	-$4.04
Price to Book	1.26
Revenue Per Employee	$0.00

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc